Get the Stockscreener App
2.00
2.44%
-0.05
After Hours:
2.05
0.05
+2.50%
Climb Bio Inc stock is traded at $2.00, with a volume of 623.68K.
It is down -2.44% in the last 24 hours and up +1.01% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$2.05
Open:
$2.05
24h Volume:
623.68K
Relative Volume:
0.83
Market Cap:
$135.53M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-0.9302
EPS:
-2.15
Net Cash Flow:
$57,000
1W Performance:
-4.76%
1M Performance:
+1.01%
6M Performance:
+57.48%
1Y Performance:
-47.64%
1-Day Range:
$1.93
$2.10
1-Week Range:
$1.93
$2.18
52-Week Range:
$1.05
$4.34
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
2.00 | 138.92M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | William Blair | Outperform |
| Oct-13-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
View All
Climb Bio Inc Stock (CLYM) Latest News
Can Climb Bio Inc. stock maintain operating margins2025 Market Outlook & Fast Momentum Stock Entry Tips - newser.com
Momentum divergence signals in Climb Bio Inc. chartSell Signal & Verified Stock Trade Ideas - newser.com
Can momentum traders help lift Climb Bio Inc.2025 Trade Ideas & Stepwise Trade Signal Implementation - newser.com
Will Climb Bio Inc. stock go up soonJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Climb Bio to Present at Upcoming Investor Conferences - The Manila Times
Is Climb Bio Inc. stock entering bullish territoryTrend Reversal & Trade Opportunity Analysis - newser.com
How sustainable is Climb Bio Inc. stock dividend payout2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
Why Climb Bio Inc. stock is recommended by analysts2025 Earnings Surprises & Stepwise Trade Signal Implementation - newser.com
Visualizing Climb Bio Inc. stock with heatmaps2025 Market WrapUp & Stock Timing and Entry Methods - newser.com
Predicting Climb Bio Inc. trend using moving averagesQuarterly Trade Summary & Advanced Swing Trade Entry Alerts - newser.com
Strategies to average down on Climb Bio Inc.Analyst Downgrade & Reliable Price Action Trade Plans - newser.com
Using R and stats models for Climb Bio Inc. forecastingEarnings Overview Report & Short-Term High Return Ideas - newser.com
Has Climb Bio Inc. formed a bullish divergenceMarket Rally & Risk Managed Investment Strategies - newser.com
What institutional flow reveals about Climb Bio Inc.Weekly Investment Summary & Community Consensus Stock Picks - newser.com
William Blair Initiates Coverage of Climb Bio (CLYM) with Outperform Rating on Autoimmune Drug Potential - Insider Monkey
10 Best Stocks Under $3 to Invest In - Insider Monkey
Climb Bio, Inc. (NASDAQ:CLYM) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Climb Bio’s Promising Phase 1b Study on Budoprutug for Lupus: A Market Game-Changer? - TipRanks
Climb Bio’s Phase 2 Study on Budoprutug: A Potential Game-Changer in Nephrology - TipRanks
Will Climb Bio Inc. stock remain a Wall Street favoriteJuly 2025 Market Mood & Risk Managed Investment Signals - Fundação Cultural do Pará
Climb Bio’s Promising ITP Study: A Potential Game-Changer for Investors - TipRanks
Climb Bio’s Budoprutug Study: A Promising Step Forward - TipRanks
Published on: 2025-10-27 09:11:02 - newser.com
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Climb Bio Inc Stock (CLYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pimblett Emily | SVP, Finance & CAO |
Jun 20 '25 |
Sale |
1.24 |
1,242 |
1,540 |
18,888 |
| Pimblett Emily | SVP, Finance & CAO |
Mar 20 '25 |
Sale |
1.31 |
1,199 |
1,571 |
15,130 |
| Pimblett Emily | CHIEF ACCOUNTING OFFICER |
Dec 19 '24 |
Sale |
2.02 |
1,235 |
2,495 |
11,329 |
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):